Nuñez-Gil, Ivan JFernandez-Perez, CristinaEstrada, VicenteBecerra-Muñoz, Victor MEl-Battrawy, IbrahimUribarri, AitorFernandez-Rozas, InmaculadaFeltes, GiselaViana-Llamas, Maria CTrabattoni, DanielaLopez-Pais, JavierPepe, MartinoRomero, RodolfoCastro-Mejia, Alex FCerrato, EnricoAstrua, Thamar CapelD'Ascenzo, FabrizioFabregat-Andres, OscarMoreu, JoseGuerra, FedericoSignes-Costa, JaimeMarin, FranciscoBuosenso, DaniloBardaji, AlfredoRaposeiras-Roubin, SergioElola, JavierMolino, AngelGomez-Doblas, Juan JAbumayyaleh, MohammadAparisi, AlvaroMolina, MariaGuerri, AsuncionArroyo-Espliguero, RamonAssanelli, EmilioMapelli, MassimoGarcia-Acuña, Jose MBrindicci, GaetanoManzone, EdoardoOrtega-Armas, Maria EBianco, MatteoTrung, Chinh PhamNuñez, Maria JoseCastellanos-Lluch, CarmenGarcia-Vazquez, ElisaCabello-Clotet, NoemiJamhour-Chelh, KarimTellez, Maria JFernandez-Ortiz, AntonioMacaya, Carlos2023-02-092023-02-092020-10-15Núñez-Gil IJ, Fernández-Pérez C, Estrada V, Becerra-Muñoz VM, El-Battrawy I, Uribarri A, et al. Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry. Intern Emerg Med. 2021 Jun;16(4):957-966http://hdl.handle.net/10668/16570Recently the coronavirus disease (COVID-19) outbreak has been declared a pandemic. Despite its aggressive extension and significant morbidity and mortality, risk factors are poorly characterized outside China. We designed a registry, HOPE COVID-19 (NCT04334291), assessing data of 1021 patients discharged (dead or alive) after COVID-19, from 23 hospitals in 4 countries, between 8 February and 1 April. The primary end-point was all-cause mortality aiming to produce a mortality risk score calculator. The median age was 68 years (IQR 52-79), and 59.5% were male. Most frequent comorbidities were hypertension (46.8%) and dyslipidemia (35.8%). A relevant heart or lung disease were depicted in 20%. And renal, neurological, or oncological disease, respectively, were detected in nearly 10%. Most common symptoms were fever, cough, and dyspnea at admission. 311 patients died and 710 were discharged alive. In the death-multivariate analysis, raised as most relevant: age, hypertension, obesity, renal insufficiency, any immunosuppressive disease, 02 saturation  0.999; bootstrap-optimist: 0.0018). We provide a simple clinical score to estimate probability of death, dividing patients in four grades (I-IV) of increasing probability. Hydroxychloroquine (79.2%) and antivirals (67.6%) were the specific drugs most commonly used. After a propensity score adjustment, the results suggested a slight improvement in mortality rates (adjusted-ORhydroxychloroquine 0.88; 95% CI 0.81-0.91, p = 0.005; adjusted-ORantiviral 0.94; 95% CI 0.87-1.01; p = 0.115). COVID-19 produces important mortality, mostly in patients with comorbidities with respiratory symptoms. Hydroxychloroquine could be associated with survival benefit, but this data need to be confirmed with further trials. Trial Registration: NCT04334291/EUPAS34399.enCOVID-19MortalityPrognosisRegistryScoreAgedCOVID-19FemaleHospitalizationHumansItalyMaleMiddle agedPropensity scoreRegistriesRisk assessmentRisk factorsSpainSurvival rateresearch article33165755open accessAncianoEspañaFactores de riesgoFemeninoHospitalizaciónItaliaMasculinoMedición de RiesgoPersona de mediana edadPuntaje de propensiónTasa de supervivencia10.1007/s11739-020-02543-51970-9366PMC7649104https://link.springer.com/content/pdf/10.1007/s11739-020-02543-5.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649104/pdf